|
Volumn 29, Issue 1-2, 1997, Pages 315-316
|
T10B9 action: The effect of anti-T-cell antibody mitogenicity and graft rejection on the first dose cytokine response
a,b a a a a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
AZATHIOPRINE;
CYTOKINE;
GAMMA INTERFERON;
INTERLEUKIN 2;
INTERLEUKIN 6;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY T10B9;
OKT 3;
PREDNISONE;
T LYMPHOCYTE RECEPTOR;
TUMOR NECROSIS FACTOR ALPHA;
UNCLASSIFIED DRUG;
CHILL;
CLINICAL TRIAL;
CONFERENCE PAPER;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DRUG EFFECT;
FEVER;
GASTROINTESTINAL SYMPTOM;
GRAFT REJECTION;
HEART TRANSPLANTATION;
HUMAN;
IMMUNE RESPONSE;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY GRAFT REJECTION;
MITOGENICITY;
NEUROTOXICITY;
PRIORITY JOURNAL;
ANTIBODIES, MONOCLONAL;
CYTOKINES;
GRAFT REJECTION;
HEART TRANSPLANTATION;
HUMANS;
INTERFERON TYPE II;
INTERLEUKIN-2;
INTERLEUKIN-6;
KIDNEY TRANSPLANTATION;
MUROMONAB-CD3;
RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA;
T-LYMPHOCYTES;
TRANSPLANTATION, HOMOLOGOUS;
TUMOR NECROSIS FACTOR-ALPHA;
|
EID: 0030936444
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(96)00281-3 Document Type: Conference Paper |
Times cited : (3)
|
References (8)
|